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CORRESPONDENCE 
Properties of a disease-specific prion probe 
To the editor: 
In a recently published article 1, Paramithiotis 
et al. describe antibodies specific for the 
prion Tyr-Tyr-Arg (YYR) repeat motif. 
These antibodies interact with the patholog-
ical isoform of the prion protein (PrPSC), 
but not with the normal cellular isoform 
(Prpe). Because of this restricted specificity, 
they suggest that YYR-specific antibodies 
could be useful for the diagnosis and treat-
ment of prion diseases (Fig. O. The mono-
clonal antibodies, all of the IgM isotype, 
were produced by immunizing mice with a 
synthetic peptide (CYYRRYYRYY). When 
coupled to magnetic beads, these YYR-spe-
cific antibodies immunoprecipitate Prpsc 
much more efficiently than Prpe. Notably, 
the Paramithiotis study did not rely on anti-
bodies to YYR for specific detection of PrP. 
Their immunoblots were not ultimately 
probed with Prpsc-specific antibodies, but 
rather with 'regular' antibodies. The latter 
can detect PrP (but do not distinguish 
between Prpsc and Prpe) in a precipitate 
that could include any protein containing 
solvent-accessible tyrosine and arginine 
residues. 
This report is notably similar to that of 
Korth et al. 2, who described a Prpsc-specific 
IgM (designated 15B3) after immunizing 
with full -length recombinant bovine PrP. 
The 15B3 epitope consists of three separate, 
linear segments of PrP (15B3-1, 15B3-2 and 
15B3-3) . The YYR epitope (bold) identified 
by Paramithiotis et al. is included in or 
located near two of the 15B3 segments 
(underlined): GSDYEDRYYR (l5B3-1) and 
YYRPVDOYS (l5B3-2). Thus, these two 
independent studies relying on the same 
method of immunoprecipitation have iden-
tified similar IgM antibodies interacting 
with the same region on PrP, and possibly 
with the same YYR motifs. 
The new reagents described could put an 
end to the quest for a Prpsc-specific anti-
body. Because the authors envision thera-
peutic use of the described antibodies, 
however, it seems appropriate to emphasize 
that YYR-specific antibodies could interact 
with any protein with tyrosine and arginine 
residues on its surface. In regard to Prpsc 
detection, it should be noted that no diag-
nostic application of 15B3 has been 
reported since the report of Korth et al. was 
published in in 1997. The availability of new 
diagnostic tests sensitive enough to ensure 
the protection of public health is an impor-
tant issue3. For the design of such tests, there 
remains the choice between high-affinity 
antibodies that recognize both Prpsc and 
Figure 1 Conversion of the normal form of the prion protein (Prpc) to the pathogenic form (PrPSC) 
produces protein aggregates such as these. Scale bar, 20 ~m. 
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Prpe but require prior elimination of Prpe, 
and lower-affinity but Prpsc-specific anti-
bodies. 
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Paramithiotis et at. reply: 
We did indeed use 'regular' PrP-specific anti-
bodies for the immunoblotting and ELISA 
detection of Prpsc captured by our YYR-spe-
cific antibodies. However, we were also able 
to detect native Prpsc at the surface of 
scrapie-infected sheep dendritic cells using 
direct immunostaining protocols l . In addi-
tion, because YYR-specific antibodies do not 
react with brain homogenate by 
immunoblot, and do not seem to possess sig-
nificant surface reactivity on normal dissoci-
ated neurons or lymphoid cells, this epitope 
is apparently rare in the structural proteome. 
Gorochov and Deslys perceive a parallel 
between our hypothesis-driven discovery of 
the YYR epitope l and a previous report of a 
single putatively Prpsc-specific monoclonal 
antibody, 15B3 (ref. 2). We used biophysical 
methods to define the minimal peptide epi-
tope YYR, then used YYR to immunize wild-
type animals. This generated polyclonal 
antibodies and more than 40 Prpsc-selective 
monoclonal antibodies (including three 
IgGs). The 15B3 monoclonal antibody, in 
contrast, was raised in Prnp-I- mice immu-
nized with recombinant bovine PrP. The 
15B3 epitope was defmed by reactivity to a 
'gridded array' of bovine PrP 13-mer pep-
tides staggered in register on a cellulose 
membrane2• Using this method, the 15B3 
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CORRESPONDENCE 
epitope was interpreted to be discontinuous, 
comprising three segments that occupy 
-20% of the sequence of the PrP structured 
domain. If YYR were the lSB3 epitope, this 
sequence would have been centrally located 
in all three segments; however, only one seg-
ment contained the complete YYR motif at 
the extreme N terminus (segment II). In 
addition, the peptide-spotting method for 
epitope mapping revealed that several pep-
tides recognized by lSB3 do not contain a 
YYR motif, whereas several peptides not rec-
ognized by lSB3 do contain YYR. The data, 
as presented2, indicate that YYR is not the 
lSB3 epitope. 
The usefulness of the YYR epitope in 
prion immunotherapy or immunoprophy-
laxis remains open until confirmed by exper-
12 
imental tests, as do its potential diagnostic 
applications. 
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